A Phase 3 interventional study of Budesonide and Pulmicort Turbuhaler in Asthma, sponsored by AstraZeneca. Completed at 6 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2011-03-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 56th largest by enrollment of the 108 interventional ones that give a count, is one of 3 that started in 2009, is one of 51 in phase 3, and was the 61st registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 148th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2009, is one of 121 in phase 3, and was the 122nd registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to show similarity of efficacy on Pulmicort Respules 1.0 mg/day or 2.0 mg/day for 6 weeks in the treatment period and the corresponding doses of Pulmicort Turbuhaler 400 μg/day or 800 μg/day for 4 weeks in the observation period in Japanese adult asthmatic patients with age of 16 years or older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Four weeks treatment with either Pulmicort Turbuhaler at a dose of 400 μg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily
Drug: Budesonide
Pulmicort Turbuhaler at a dose of 200 μg twice daily and Pulmicort Respules at a dose of 0.5 mg twice daily or 1.0 mg once daily (low dose)
Drug: Pulmicort Turbuhaler
Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
Also known as: Pulmicort
Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
Morning Peak Expiratory Flow (mPEF)
Change in morning peak expiratory flow (mPEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Evening Peak Expiratory Flow (ePEF)
Change in evening peak expiratory flow (ePEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Asthma Symptom Score (Daytime); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)
Change in Asthma symptom score (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Asthma Symptom Score (Night-time); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)
Change in Asthma symptom score (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Asthma Symptom Score (Total); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)
Change in Asthma symptom score (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Use of Rescue Medication (Daytime)
Change in Use of rescue medication (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Use of Rescue Medication (Night-time)
Change in Use of rescue medication (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Use of Rescue Medication (Total)
Change in Use of rescue medication (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Night-time Awakenings Due to Asthma Symptoms
Change in Night-time awakenings due to asthma symptoms from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Forced Expiratory Volume in 1 Second (FEV 1.0)
Change in Forced Expiratory Volume in 1 second (FEV 1.0) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Forced Vital Capacity (FVC)
Change in Forced Vital Capacity (FVC) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
Time frame: 6 weeks
Number of Participants With Adverse Events (AEs)
Number of participants with AEs reported during the period on Pulmicort Respules
Time frame: 6 weeks
Outpatients, male and female ≥ 16 years with stable asthma
| Milestone | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Started | 108 |
| Patients who received pulmicort respules | 105 |
| Completed | 99 |
| Not completed | 9 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Incorrect enrolment | 1 |
Change in morning peak expiratory flow (mPEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| L/min | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Morning Peak Expiratory Flow (mPEF) | 3.3 ± 21.4 |
Change in evening peak expiratory flow (ePEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| L/min | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Evening Peak Expiratory Flow (ePEF) | 3.8 ± 18.1 |
Change in Asthma symptom score (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| Scores on a scale | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Asthma Symptom Score (Daytime); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms) | 0.018 ± 0.198 |
Change in Asthma symptom score (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| Scores on a scale | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Asthma Symptom Score (Night-time); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms) | 0.022 ± 0.185 |
Change in Asthma symptom score (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| Scores on a scale | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Asthma Symptom Score (Total); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms) | 0.039 ± 0.346 |
Change in Use of rescue medication (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| puffs | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Use of Rescue Medication (Daytime) | 0.017 ± 0.160 |
Change in Use of rescue medication (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| puffs | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Use of Rescue Medication (Night-time) | 0.044 ± 0.220 |
Change in Use of rescue medication (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| puffs | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Use of Rescue Medication (Total) | 0.061 ± 0.317 |
Change in Night-time awakenings due to asthma symptoms from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| awakenings | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Night-time Awakenings Due to Asthma Symptoms | -0.004 ± 0.165 |
Change in Forced Expiratory Volume in 1 second (FEV 1.0) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| L | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Forced Expiratory Volume in 1 Second (FEV 1.0) | 0.079 ± 0.244 |
Change in Forced Vital Capacity (FVC) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| L | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Forced Vital Capacity (FVC) | 0.105 ± 0.283 |
Number of participants with AEs reported during the period on Pulmicort Respules
| Participants | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Number of Participants With Adverse Events (AEs) | 50 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pulmicort Turbuhaler and Pulmicort Respules | — | 0/108 (0%) | 7/105 (6.7%) |
| Event | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| NasopharyngitisRenal and urinary disorders | 7/105 |
| Age Continuous(Years) | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Mean | 43.9 ± 13.4 |
| Sex: Female, Male(Participants) | Pulmicort Turbuhaler and Pulmicort Respules |
|---|---|
| Female | 73 |
| Male | 33 |
The record gives a start of Feb 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide